Idorsia Ltd. (0RQE)

Overview

Idorsia Ltd is a pioneering biopharmaceutical entity based in Allschwil, Switzerland, that embarks on the journey of discovery, development, and commercialization of innovative drugs to meet the unmet medical needs across the globe. Founded in 2017, the company has rapidly distinguished itself in the pharmaceutical industry by focusing on the research and development of therapeutic solutions for a wide array of conditions, including central nervous system (CNS) disorders, cardiovascular ailments, immunological disorders, and orphan diseases. Through strategic collaborations with leading pharmaceutical companies like Janssen Biotech Inc., Mochida Pharmaceutical, Hoffmann-La Roche Inc., and Neurocrine Biosciences, Inc., Idorsia is at the forefront of developing groundbreaking treatments that promise to revolutionize healthcare for patients around the world.

Products and Services

• PIVLAZ (clazosentan)

  Available in 150 mg, PIVLAZ is a testament to Idorsia's commitment to cardiovascular health, specifically tailored for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms following an aneurysmal subarachnoid hemorrhage. This product underscores the company's expertise in creating targeted solutions for critically acute conditions.

• QUVIVIQ (daridorexant)

  In doses of 25 and 50 mg, QUVIVIQ addresses the pervasive challenge of insomnia among adults. This innovative treatment is a hallmark of Idorsia's focus on CNS disorders, showcasing the company's dedication to improving sleep health and, by extension, overall wellbeing.

• Aprocitentan Collaboration

  In partnership with Janssen Biotech Inc., Idorsia is co-developing aprocitentan and its derivative compounds, demonstrating a strong commitment to advancing cardiovascular health solutions. This collaboration is aimed at combining expertise and resources to bring novel treatments for hypertension and related conditions to the market.

• Daridorexant License Agreement with Mochida Pharmaceutical

  This strategic license agreement encompasses the supply, co-development, and co-marketing of daridorexant with Mochida Pharmaceutical. It reflects Idorsia's strategy of leveraging partnerships to enhance the global availability and therapeutic impact of its insomnia treatment solutions.

• Cancer Immunotherapy Development with Hoffmann-La Roche

  Through a landmark agreement with Hoffmann-La Roche Inc., Idorsia is set to co-develop and market innovative compounds in the cancer immunotherapy domain. This collaboration underscores the company's commitment to combatting cancer through immune system modulation.

• ACT-709478 Development for Epilepsy with Neurocrine Biosciences

  In a vital collaboration with Neurocrine Biosciences, Inc., Idorsia is advancing the development and commercialization of ACT-709478, currently in Phase II clinical trial for treating epilepsy. This partnership highlights the company's focus on addressing neurological disorders through cutting-edge research.